CIDRAP is leading an international collaborative effort to develop an influenza vaccines R&D roadmap (IVR), aimed at accelerating progress toward universal or broadly protective influenza vaccines, one of the most critical global public-health priorities. The IVR serves as a valuable tool to advance the development of novel vaccines that improve the breadth and durability of protection from influenza infection and severe disease. It encompasses incremental improvements in strain-specific seasonal vaccines, as well as transformational changes in vaccine technology designed to induce broad, durable protection against seasonal and pandemic influenza viruses.
CIDRAP engaged a large group of stakeholders, representing a range of scientific disciplines, public and private sectors, and international communities, to identify key research priorities and build consensus toward achievable strategic goals and associated milestones. The IVR also focuses on developing effective strategies for communications, advocacy, and monitoring R&D progress over time.
The IVR project is funded by the Wellcome Trust (London, UK), and is guided by a small steering group, with members from the World Health Organization, the Sabin Vaccine Institute, the Bill and Melinda Gates Foundation, the Wellcome Trust, and the Global Funders Consortium for Universal Influenza Vaccine Development. CIDRAP and the IVR Steering Group also established a diverse international taskforce to provide expertise in a variety of specialized areas relevant to vaccine R&D, including influenza virology, epidemiology, immunology, vaccinology, clinical trials, and regulatory science.